Alnylam Pharmaceuticals this week announced data from a phase I extension study of its RNAi-based liver cancer therapy ALN-VSP, which showed the drug could control disease for more than six months in the majority of patients treated.
The findings include a complete response from an endometrial cancer patient with multiple liver metastases.
The extension study enrolled patients from a previous phase I trial who achieved stable disease after four months or longer of ALN-VSP treatment. Main objectives included continued evaluation of safety and tolerability and assessment of disease response.
Alnylam previously announced that it would only advance ALN-VSP into phase II testing with a partner, and that it expected to forge such a deal this year (GSN 5/10/2012).